Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 7125718 | Long-term outcome in Felty's syndrome. | 1982 Oct | Felty's syndrome has again been shown to be a severe form of systemic rheumatoid disease characterised by severe joint involvement, many extra-articular features, and a high incidence of infection. In addition we have shown that splenectomy was not protective for infections and in fact may on occasion contributed to infection. Furthermore, although most patients had an increase in white blood cell count after splenectomy, 50% of patients without splenectomy showed a similar increase in white blood cell counts at follow-up. Mortality in Felty's syndrome was high, with infection being the main cause of death. | |
| 6673369 | [Hemolytic transfusion incident caused by a Kidd-antibody, anti-Jka]. | 1983 Nov 11 | A severe haemolytic transfusion reaction due to anti-Jka, is described. The antibody was not detected in the cross-match test in saline and 22% bovine serum albumin after incubation at 4, 20 and 37 degrees C. This observation shows that the indirect antiglobulin test (= indirect Coombs reaction), which is able to reveal such antibodies, should be routinely performed in all cases with a history of transfusion and/or pregnancy. | |
| 321165 | Restoration by levamisole of low E-rosette forming cells in patients suffering from variou | 1977 Feb | One hundred and fifteen patients presenting with various clinical conditions (multiple sclerosis, recurrent infections, HBAg-positive chronic hepatitis, Crohn's disease, ataxia-telangiectasia, SSPE and atopic dermatitis) were evaluated for E-rosette formation. Forty-two patients were found to have a low number of E-rosettes. Eighteen patients with low E-rosettes were treated with levamisole, an anti-anergic chemotherapeutic agent, and were compared with an untreated control group of sixteen patients. Levamisole treatment significantly increased low E-rosettes in these patients and this was accompanied by a remarkable clinical improvement and a significant reduction of haemolytic complement activity. Therefore our results suggest the important role of T-cell function in these various clinical conditions, in which cell-mediated immunity is thought to play a major role. | |
| 449278 | Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. | 1979 Jun | The topographic distribution, population density, and ultrastructural features of metachromatic cells (mast cells and basophilic leukocytes) were studied in lung biopsies from five control patients and 17 patients with fibrotic lung disorders. The great majority of metachromatic cells were mast cells. The average number of metachromatic cells per square millimeter of tissue section was much larger in patients with fibrotic lung disorders (45.8 +/- 6.5) than in control patients (2.6 +/- 1.6). In control patients, mast cells were most frequently seen in subpleural and perivascular connective tissue. In contrast, the vast majority of mast cells in patients with fibrotic lung disorders was present in thickened, fibrous alveolar septa; mast cells also were found within the alveolar epithelial layer and alveolar lumina. The quantitative distribution of different types of mast cell granules differed in the two groups of patients: granules composed of scrolls were more frequent in control patients, and granules of the combined type (containing mixtures of different components within the same granule) were more frequent in patients with fibrotic lung disorders. Mast cells in the latter patients appeared to migrate through defects in the basement membrane into the epithelial layer and alveolar lumina; mast cells in these areas often showed reduced numbers of granules and disorganized granule content. These changes suggest that pulmonary parenchymal mast cells in fibrotic lung disorders undergo a chronic process of partial degranulation which differs from that found in anaphylaxis; this chronic release of mast cell products may contribute to the continuing alveolar injury and the ventilation-perfusion inequalities observed in the fibrotic lung disorders. | |
| 6165687 | Studies on Paul-Bunnel (P-B) antigen-antibody system. I. Two distinct P-B antigens. | 1981 | The multiple nature of heterophile, Paul-Bunnel (P-B) antigen has been suggested by our previous studies as well as those of others. In the present study, two distinct antigens of P-B specificity were defined by means of hemagglutination and immunodiffusion tests in agarose gel; one antigen (BS) was shared by bovine (BRBC) and sheep red blood cells (SRBC) and another antigen (B) was limited to BRBC. Both anti-BS and anti-B antibodies were shown to be present in sera of 106 patients with infectious mono-nucleosis (IM) whereas they were virtually absent from the sera of the vast majority of patients with diseases other than IM and normal sera. Absorption and agglutination inhibition tests demonstrated the presence of BS and B antigens on horse erythrocytes. Goat erythrocytes were also shown to possess BS antigen, however, B antigen was found on erythrocytes of some but not all individual goats. By means of the previously established procedure, BS antigen was extracted from stromata of BRBC, SRBC and erythrocytes of horse and goat, and B antigen from BRBC and erythrocytes of some goats. BS and B antigens were also extracted from bovine lymphocytes and murine thymus and spleen tissues but not murine erythrocytes. | |
| 6366617 | [Effects of nandrolone decanoate on bone mineral content and intestinal absorption of calc | 1984 Jan 28 | To evaluate the effects of a long-term treatment with nandrolone decanoate on metabolism of the skeleton, a double-blind randomized study was carried out in women with joint diseases without metabolic bone derangement. Ten patients were treated with 50 mg of nandrolone decanoate every three weeks for two years; in six subjects a treatment with placebo was performed. As it concerns plasma calcium and phosphate, serum alkaline phosphatase, urinary excretion of calcium, phosphate, hydroxyproline and cAMP, as parathyroid index, it was not observed significant differences in the two examined groups. While in placebo group at the end of the study the intestinal radiocalcium remained unchanged and bone mineral content showed a slight decrease, on the contrary nandrolone decanoate treatment promoted a significant improvement in intestinal calcium absorption and an increase in bone mineral content. | |
| 7075647 | Binding of aprindine and moxaprindine to human serum, alpha 1-acid glycoprotein and serum | 1982 | A comparison was made between the binding of the anti-arrhythmic agents aprindine and moxaprindine to human serum, to human serum albumin (HSA), to alpha 1-acid glycoprotein (alpha 1-AGP) and to a mixture of HSA and alpha 1-AGP. In serum from healthy volunteers (n = 4) the binding of aprindine-HCl 5 micrograms/ml (13.8 microM) was 93.8% (SD +/- 1.0), and that of moxaprindine-HCl 5 micrograms/ml (12.8 microM) was 94.15 (SD +/- 1.1). Their binding to the mixture of alpha 1-AGP and albumin approximated their binding to serum. For alpha 1-AGP, the binding was similar for both compounds, whereas for HSA the binding of aprindine was more pronounced than that of moxaprindine: for both products the affinity coefficient for binding to alpha 1-AGP was about 100 times greater than that for binding to albumin. In serum from rheumatoid patients and from patients with renal failure a small but significant increase in binding of aprindine and moxaprindine was observed, approximately 1%. Increased and decreased binding was seen in serum from cirrhotic patients; for example, for aprindine the range in cirrhosis was 96.7%-79.8%, and the range in controls was 95.0%-92.4%. Free drug fraction and alpha 1-AGP concentration were inversely correlated. The results show that alpha 1-AGP plays an important role in the binding of aprindine and moxaprindine, and that alteration in the binding of the two compounds in disease states to a large extent can be explained by changes in serum alpha 1-AGP concentration. | |
| 6348977 | Serum antibodies to Aspergillus fumigatus in patients with rheumatic diseases. | 1983 Jun | IgG and IgA serum antibodies to Aspergillus fumigatus were determined in 47 patients with rheumatic disorders, 4 patients with pulmonary aspergillosis associated with rheumatic disease, and in 36 healthy controls. Antibody titres determined by indirect immunofluorescence were comparable in patients with rheumatic diseases and in controls, except for 2 patients with IgG antibody titres within the upper range of patients with aspergillosis. IgG antibody levels to 2 partially purified A. fumigatus antigens (I and VIII), determined by enzyme-linked immunosorbent assay (ELISA), were higher in rheumatic patients than in controls and with antigen VIII the difference reached statistical significance for all subgroups of rheumatic patients. IgA antibody levels by ELISA were also increased in rheumatic patients compared with the control group: IgA levels against antigen I fell within the range of patients with aspergillosis in 7 patients with rheumatic disorders. This suggests that some rheumatic patients are more strongly sensitized to Aspergillus antigens than normal subjects. | |
| 1151954 | Specificity of SLE serum antibody for single-stranded and double-stranded DNA configuratio | 1975 Jun | The solid phase immunoassay for the measurement of serum antibody to double and single-stranded DNA is described. The technique allows a more accurate definition of the antibody specificity of SLE sera as defined by inhibition techniques. The clinical usefulness of immunologic assays in the management of patients with SLE is described, including measurement of urine light chain protein concentration. A core discussion is provided to illustrate how such a panel of tests is used in management. | |
| 1091093 | [Blood proteolytic enzyme inhibitors and their clinical study]. | 1975 Jan | Data on biochemistry, physiological significance and clinical investigations of two main inhibitors of proteinases in human blood serum (alpha 1-antitrypsin and alpha 2-macroglobulin) are reviewed. Physico-chemical properties of the inhibitors, mechanisms of their interaction with proteinases and methods for determination are discussed. Modification of the specificity of some proteinases by alpha 2-macroglobulin, which probably plays a significant role in the regulation of enzymatic systems of proteolysis in blood, is considered. The use of the inhibitors of proteolysis for diagnostics of pathological processes is discussed. Data on the alpha 1-antitrypsin deficiency and its relation to the development of degenerative diseases in lungs are reviewed. | |
| 4419123 | Acute rheumatic fever. | 1974 Oct 19 | While rheumatic fever is relatively uncommon except where there are poor and crowded living conditions, sporadic acute attacks continue to occur in a family or pediatric medical practice. The physician's role in management of the sore throat in the diagnosis of suspected cases of rheumatic fever and in follow-up for continued prophylaxis is discussed. The frequency of admissions and presenting features of 159 patients with acute rheumatic fever is reviewed. Continued surveillance is required if we are to achieve a further reduction in attack rate and complications. | |
| 1171140 | Detection and quantitation in plasma and synovial fluid of a fragment of human C4 with alp | 1975 Jul | A newly identified fragment of human C4 was detected, using a particular antiserum, in human serum after activation by heat-aggregated immunoglobulins, but not after activation of the complement alternative pathway. This fragment was shown to have a sedimentation velocity of approximately 2.5S, to be heat stable, and to exhibit alpha mobility in immunoelectrophoresis. This C4alpha mobility fragment was not generated in human C4 deficient serum but was generated in human C2 deficient serum after incubation with heat-aggregated immunoglobulin. After precipitation of native C4 and its higher molecular weight fragments from serum by polyethylene glycol, it was possible to quantitate the lower molecular weight C4 alpha mobility fragment by radial immunodiffusion. In kinetic experiments, it was shown that the C4alpha mobility fragment was generated after some delay when compared to the disappearance of C4 hemolytic activity. Quantitation of the C4alpha mobility fragment may be of further use in human diseases for the evaluation of the catabolism of C4: joint fluids of patients suffering from rheumatoid arthritis contained high levels of the C4alpha mobility fragment, and low concentrations were found in patients with degenerative joint disease. | |
| 366146 | A critical review of the effect of levamisole in rheumatic diseases other than rheumatoid | 1978 | Levamisole has been used in several rheumatic diseases other than rheumatoid arthritis (RA). These include systemic lupus erythematosus (SLE), polymyositis/dermatomyositis, scleroderma, Sjögren's syndrome, psoriatic arthritis, ankylosing spondylitis, Reiter's syndrome and juvenile rheumatoid arthritis. Most of the published data have either been case reports including very few patients or have been concerned with specific clinical or laboratory assessments. It was therefore very difficult to make any reliable evaluation of the effect of levamisole in these conditions. Levamisole might have had some beneficial effect in some of the diseases listed but properly conducted, controlled trials are necessary before any definitive assessment can be made. | |
| 6980008 | Antibodies to SS-B in chronic inflammatory connective tissue diseases. Relationship with H | 1982 Jun | SS-B antigen, purified from rabbit thymus, was used in an indirect enzyme immunoassay to demonstrate the presence of IgG-, IgA-, and IgM-type SS-B antibodies in sera from patients with well-defined and characterized chronic inflammatory connective tissue disease. High levels of antibodies to SS-B were found in patients with primary and secondary Sjögren's syndrome. Patients with Sjögren's syndrome secondary to systemic lupus erythematosus had significantly higher SS-B antibody values than patients with Sjögren's syndrome secondary to rheumatoid arthritis or patients with rheumatoid arthritis or systemic lupus erythematosus, alone. Two patients with rheumatoid arthritis without secondary Sjögren's syndrome also had a markedly elevated level of antibodies to SS-B. Antibodies of all immunoglobulin classes were found, although the highest values were either IgG- or IgM-type. In primary Sjögren's syndrome, antibody values to SS-B were higher in patients with HLA-Dw2 and/or HLA Dw3 than in those with other HLA-Dw types. We conclude that these antigens or specific immune-response genes close to the D region may be important for the development of antibodies to SS-B. | |
| 6111850 | Immunology of chorioretinal disorders. | 1981 Mar | Because of its uniqueness, the eye has long been a favored site for immunological study. It is a highly active tissue immunologically, with virtually all types of immune reactions present. This article reviews the ocular immune response, chorioretinal diseases with immunologic features, and immunology of ocular tumors. Immunologic data is discussed as it relates to the pathogenesis, clinical features, and therapy of chorioretinal disease. | |
| 6241918 | [Demonstration of C3-binding circulating immune complexes using Raji, conglutinin and anti | 1984 Feb | There remains no doubt at the present time, that the appearance of circulating immune complexes in illness accompanying vasculitis and for glomerulonephritis correlates with the severity of disease. Moreover, immune complexes are of diagnostic importance where infections with a chronic development or neoplastic diseases are concerned. The choice of IC test system should incorporate their essential biological functions and identify those IC that activate the complement cascade both by the classical and the alternative route. The detection of IC bound C3 cleavage products (C3b, C3bi, C3d) represents the key to identification of a wide range of IC. Of the presently available methods Raji cell test, conglutinin- and anti C3-IC assay, on critical appraisal, the anti C3-IC assay represents the most applicable way of defining complement binding IC. The advantage of this system is that appreciable disturbances and limitations that influence other systems do not affect the antigen-antibody reaction which is the core of the anti C3 assay. | |
| 850778 | Dissociation of acetylsalicylic acid in blood and joint fluid. | 1977 | Assay method in blood of 30 patients, who had ingested 0.6 g buffered aspirin, showed earlier appearance of acetylsalicylate (ASA) than of de-acetylated salicylate (SA); the values for ASA averaged 7.7 min, and for SA, 10.9 min. Similarly in joint fluid, ASA appeared earlier than SA; the values of ASA averaged 19.4 min, and those for SA, 21.9 min. Transport times did not differ significantly between ASA and SA in most types of synovitis. Close to maximum concentrations in blood averaged 18.9 mg/l for total salicylates (TSA), 3.3 mg/l for ASA, and 23.3 mg/l for SA, whereas maximum concentrations in joint fluid averaged 15.7 mg/l for TSA, 2.5 mg/l for ASA, and 14.5 mg/l for SA. ASA in blood initially consituted 65% of TSA and decreased to less than measurable amounts 75 min after intake. Joint fluid initially contained a somewhat smaller maximal proportion of ASA, but de-acetylation progressed more slowly than in blood; ASA decreased to undetectable levels within 140-145 min after intake. | |
| 3875652 | Specific and shared idiotypes found on hybridoma anti-DNA autoantibodies derived from rheu | 1985 Oct | The idiotype determinants found on hybridoma anti-DNA autoantibodies produced from the fusion of peripheral blood lymphocytes from 13 systemic lupus erythematosus (SLE) and five rheumatoid arthritis (RA) patients with the GM 4672 human lymphoblastoid line were analyzed. A total of 47 SLE and 21 RA hybridomas were studied, of which 26 SLE and 10 RA produced anti-DNA autoantibodies. Rabbit antisera, raised to six of the SLE hybridoma anti-DNA IgM antibodies, were rendered idiotype specific by multiple absorptions on human IgM and IgG immunoabsorbent columns. In direct binding radioimmunoassays, all six anti-idiotype antisera reacted specifically with the anti-DNA antibody used as immunogen. In competition studies, five anti-idiotype antisera were able to inhibit the binding of their homologous idiotype to DNA-coated tubes. In addition, DNA and polynucleotides inhibited the binding of the five idiotypes to anti-idiotype-coated tubes, suggesting that these anti-idiotypes react with idiotype determinants located within the antigen-combining sites of the anti-DNA antibody molecules. Shared idiotypes were detected among the 68 hybridoma antibodies by direct binding studies on anti-idiotype-coated tubes. Our results revealed that 58% (21/36) of the anti-DNA antibodies and 16% (5/32) of the non-DNA-binding antibodies reacted with at least one anti-idiotype serum. Five anti-idiotype antisera reacted only with hybridoma anti-DNA antibodies from SLE patients. The other anti-idiotype antiserum reacted with both SLE- and RA-derived hybridoma anti-DNA and non-DNA-binding antibodies. These studies indicate that some anti-idiotype antisera may detect specific idiotypes found only on SLE-derived anti-DNA auto-antibodies, whereas other antisera detect shared idiotypes found on both RA and SLE DNA-binding and non-DNA-binding antibodies. | |
| 68627 | [Clinical significance and problems of technique in the immunochemical determination of th | 1977 May 13 | Immunochemical determination of the third complement (C) component C 3 as beta 1 C/beta 1 A protein has found extensive use in the clinical evaluation of immunopathological conditions. C 3 changes are associated with inborn C defects and acquired diseases. In the latter case, diminished C3 levels are of the greatest practical relevance. Reduced C 3 values are not necessarily due to "classical" antibody-mediated C activation, as in immune-complex diseases, but may be caused also by "alternative" pathway activation and decreased C 3 synthesis. In addition, important technique factors have to be considered in the evaluation of immunochemically-determined C 3 values. Since the antigenic pattern of C 3 changes during in vitro ageing, not only the state of conversion of C 3 in the sample and in the reference serum (standard), but above all, the specificity of the anti-C 3-serum plays an important role in critically influencing the total error of the method. In order to avoid this error C 3 can be determined as beta 1 C protein using a beta 1 C standard which is, however, not easily available. On the other hand, beta 1 A quantitation causes less problems since standard sera usually contain C 3 as beta 1 A portein. However, an incubation period of 7 days at + 37 degrees C is necessary for complete C 3 conversion. This undesirable time delay has not yet been satisfactorily overcome by in vitro acceleration of C 3 conversion using different substances. | |
| 6972412 | Studies on Paul-Bunnell (P-B) antigen-antibody system. II. P-B antigens in extracts of lym | 1981 Jul | Preparations obtained by the chloroform-methanol extraction procedure from spleen tissues of patients with Hodgkin's disease, lymphomas, and leukemias, as well as from peripheral blood buffy coat of infectious mononucleosis (IM) patients were studied for the presence of 2 Paul-Bunnell (P-B) antigens; BS antigen shared by bovine red blood cells (BRBC) and sheep red blood cells (SRBC) and another, B antigen characteristic for BRBC. Both BS and B antigens were demonstrated by means of agglutination inhibition tests in over 40% of these extracts. None of the extracts from spleens, tonsils, and buffy coat of apparently normal human beings contained these antigens. P-B antigens of lymphoma-leukemia extracts were further purified by DEAE-Sephadex column chromatography. The purified fractions of some of these spleen extracts formed a precipitation line with IM sera, which merged into a reaction of identity with the lines formed by P-B antigens of BRBC. In studying various pathologic sera, B antigen was detected in sera of 28% of lymphoma-leukemia patients, 15% of patients with carcinomas of internal organs, and 3% of patients with systemic lupus erythematosus. On the other hand, BS antigen was found in only 3% of lymphoma-leukemia sera. These results confirmed our previous observations and indicated that both BS and B antigens are expressed as neoantigens on the patient's spleen cells as a result of pathologic processes in lymphoreticular malignancies. |